1. Combination Inhaled Therapy in COPD: The Impact of Recent Data

2. Treatment Goals for Stable COPD Management

3. Major Long-Term Impact of Exacerbations

4. Major Long-Term Impact of Severity of COPD

5. Predictors of Mortality: Multivariate Analysis

6. History of Exacerbations and Risk of Recurrence

7. Available Medications

8. Therapeutic Recommendations

9. FLAME STUDY: Effect of IND/GLY on Time to First Exacerbation Compared With SFC

10. IMPACT

11. Individualized Benefit-Risk Assessment

12. Blood Eosinophils and Prediction of Risk of Exacerbation

13. Improving Adherence Saves Costs

14. Conclusion

15. Key Studies With Triple Inhaler Therapy

16. Key Studies With Triple Inhaler Therapy

17. LABA/LAMA/ICS vs LABA/ICS: FULFIL Design

18. FULFIL: Inclusion Criteria

19. Change of FEV1 at 24 Weeks

20. Change of FEV1 at 52 Weeks

21. Effect on SGRQ Score

22. Effect on SGRQ Score (Cont.)

23. LABA/LAMA/ICS vs LABA/ICS: TRILOGY

24. TRILOGY: Inclusion Criteria

25. Effects on FEV1 and TDI Score

26. Evolution of Exacerbations

27. LABA/LAMA/ICS vs LABA/LAMA: TRIBUTE

28. TRIBUTE: Inclusion Criteria

29. Effect on Exacerbations

30. Effect on FEV1

31. Effect on SGRQ Score

32. TRIBUTE: Main Adverse Events

33. LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA: IMPACT

34. IMPACT: Inclusion Criteria

35. Evolution of Exacerbations

36. Effect on FEV1 and SGRQ Score

37. IMPACT: Results on Mortality

38. IMPACT: Incidence of Pneumonia

39. Conclusion

40. From Recent Studies to Individualization of Treatment: When to Use a Single Inhaled Triple Therapy in COPD

41. TRIBUTE: Effect on Exacerbations

42. TRIBUTE: Inclusion Criteria

43. IMPACT: Effect on Exacerbations

44. IMPACT: Inclusion Criteria

45. FLAME Study

46. IMPACT: Inclusion Criteria

47. IMPACT: Results on Mortality

48. IMPACT: Incidence of Pneumonia

49. Factors Associated With the Risk of Pneumonia in Patients Taking ICS

50. IMPACT: Incidence of Pneumonia

51. Rate of Moderate/Severe Exacerbations With FF/UMEC/VI in Patients With Blood Eosinophil Count < 150 and ≥ 150 Cells/μL

52. Blood Eosinophils and Prediction of Risk of Exacerbation

53. ICS Response Depends on Eosinophils level

54. Conclusion

55. Abbreviations

56. Abbreviations (cont)